The 10-day moving average for KURA crossed bearishly below the 50-day moving average on September 30, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 14 of 17 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 82%.
KURA moved below its 50-day moving average on September 23, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where KURA declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 82%.
The Aroon Indicator for KURA entered a downward trend on October 22, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where KURA's RSI Indicator exited the oversold zone, 30 of 34 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 88%.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 51 of 63 cases where KURA's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 81%.
Following a +9.91% 3-day Advance, the price is estimated to grow further. Considering data from situations where KURA advanced for three days, in 214 of 271 cases, the price rose further within the following month. The odds of a continued upward trend are 79%.
KURA may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Tickeron PE Growth Rating for this company is 30 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 60 (best 1 - 100 worst), indicating steady price growth. KURA’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 84 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (18.111) is normal, around the industry mean (2.973). P/E Ratio (-2.926) is within average values for comparable stocks, (-1.705). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (128.121) among similar stocks. P/S Ratio (12.821) is also within normal values, averaging (438.009).
The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. KURA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
The Stochastic Oscillator for ZBIO moved into overbought territory on October 22, 2026. Be on the watch for a price drop or consolidation in the future -- when this happens, think about selling the stock or exploring put options.
ZBIO moved below its 50-day moving average on September 23, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for ZBIO crossed bearishly below the 50-day moving average on September 24, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 4 of 4 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ZBIO declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 79%.
The Aroon Indicator for ZBIO entered a downward trend on October 22, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where ZBIO's RSI Oscillator exited the oversold zone, 9 of 10 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 90%.
The Momentum Indicator moved above the 0 level on October 22, 2026. You may want to consider a long position or call options on ZBIO as a result. In 37 of 45 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 82%.
The Moving Average Convergence Divergence (MACD) for ZBIO just turned positive on October 20, 2026. Looking at past instances where ZBIO's MACD turned positive, the stock continued to rise in 16 of 19 cases over the following month. The odds of a continued upward trend are 84%.
Following a +13.45% 3-day Advance, the price is estimated to grow further. Considering data from situations where ZBIO advanced for three days, in 115 of 130 cases, the price rose further within the following month. The odds of a continued upward trend are 88%.
ZBIO may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Tickeron Price Growth Rating for this company is 49 (best 1 - 100 worst), indicating steady price growth. ZBIO’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of 86 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (7.446) is normal, around the industry mean (2.973). P/E Ratio (-2.931) is within average values for comparable stocks, (-1.705). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (128.121) among similar stocks. P/S Ratio (1666.667) is also within normal values, averaging (438.009).
The Tickeron PE Growth Rating for this company is 99 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ZBIO’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
KURA | ZBIO | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 58 | 80 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 84 Overvalued | 86 Overvalued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 99 | 100 | |
PRICE GROWTH RATING 1..100 | 60 | 49 | |
P/E GROWTH RATING 1..100 | 30 | 99 | |
SEASONALITY SCORE 1..100 | 50 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
KURA's Valuation (84) in the Biotechnology industry is in the same range as ZBIO (86) in the null industry. This means that KURA’s stock grew similarly to ZBIO’s over the last 12 months.
KURA's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as ZBIO (100) in the null industry. This means that KURA’s stock grew similarly to ZBIO’s over the last 12 months.
KURA's SMR Rating (99) in the Biotechnology industry is in the same range as ZBIO (100) in the null industry. This means that KURA’s stock grew similarly to ZBIO’s over the last 12 months.
ZBIO's Price Growth Rating (49) in the null industry is in the same range as KURA (60) in the Biotechnology industry. This means that ZBIO’s stock grew similarly to KURA’s over the last 12 months.
KURA's P/E Growth Rating (30) in the Biotechnology industry is significantly better than the same rating for ZBIO (99) in the null industry. This means that KURA’s stock grew significantly faster than ZBIO’s over the last 12 months.
| KURA | ZBIO | |
|---|---|---|
| RSI ODDS (%) | 1 day ago 88% | 1 day ago 90% |
| Stochastic ODDS (%) | 1 day ago 81% | 1 day ago 90% |
| Momentum ODDS (%) | N/A | 1 day ago 82% |
| MACD ODDS (%) | N/A | 1 day ago 84% |
| TrendWeek ODDS (%) | 1 day ago 78% | 1 day ago 87% |
| TrendMonth ODDS (%) | 1 day ago 77% | 1 day ago 90% |
| Advances ODDS (%) | 3 days ago 79% | 3 days ago 88% |
| Declines ODDS (%) | 1 day ago 82% | 9 days ago 79% |
| BollingerBands ODDS (%) | 1 day ago 89% | 1 day ago 71% |
| Aroon ODDS (%) | 1 day ago 74% | 1 day ago 90% |
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
KURA’s FA Score shows that 1 FA rating(s) are green while ZBIO’s FA Score has 0 green FA rating(s).
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
KURA’s TA Score shows that 4 TA indicator(s) are bullish while ZBIO’s TA Score has 5 bullish TA indicator(s).
KURA (@Biotechnology) experienced а +1.65% price change this week, while ZBIO (@Biotechnology) price change was +12.95% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was -1.17%. For the same industry, the average monthly price growth was -18.21%, and the average quarterly price growth was -15.24%.
KURA is expected to report earnings on Nov 03, 2026.
ZBIO is expected to report earnings on Nov 18, 2026.
Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
A.I.dvisor indicates that over the last year, ZBIO has been loosely correlated with REPL. These tickers have moved in lockstep 41% of the time. This A.I.-generated data suggests there is some statistical probability that if ZBIO jumps, then REPL could also see price increases.
| Ticker / NAME | Correlation To ZBIO | 1D Price Change % | ||
|---|---|---|---|---|
| ZBIO | 100% | +0.53% | ||
| REPL - ZBIO | 41% Loosely correlated | +2.30% | ||
| KURA - ZBIO | 39% Loosely correlated | -0.20% | ||
| RZLT - ZBIO | 37% Loosely correlated | +4.32% | ||
| IMVT - ZBIO | 37% Loosely correlated | +2.54% | ||
| NTLA - ZBIO | 36% Loosely correlated | -4.21% | ||
More | ||||